Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

122 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group.
Spanjaart AM, Ljungman P, Tridello G, Schwartz J, Martinez-Cibrián N, Barba P, Kwon M, Lopez-Corral L, Martinez-Lopez J, Ferra C, Di Blasi R, Ghesquieres H, Mutsaers P, Calkoen F, Jak M, van Doesum J, Vermaat JSP, van der Poel M, Maertens J, Gambella M, Metafuni E, Ciceri F, Saccardi R, Nicholson E, Tholouli E, Matthew C, Potter V, Bloor A, Besley C, Roddie C, Wilson K, Nagler A, Campos A, Petersen SL, Folber F, Bader P, Finke J, Kroger N, Knelange N, de La Camara R, Kersten MJ, Mielke S. Spanjaart AM, et al. Leukemia. 2024 Sep;38(9):1985-1991. doi: 10.1038/s41375-024-02336-1. Epub 2024 Jul 23. Leukemia. 2024. PMID: 39043963 Free PMC article.
Measures to Maintain a SARS-CoV-2 Negative Inpatient Hematological Unit in the Midst of the COVID-19 Pandemic.
Cabero-Martínez A, Sánchez-Guijo F, López-Corral L, Pérez E, Avendaño A, Baile M, Cabrero M, Martín AA, Rodríguez A, Pérez B, Peña-Muñoz F, Román LG, Palomino D, López-Vázquez L, Vidriales MB, González-Diaz M, Mateos MV, Caballero MD. Cabero-Martínez A, et al. Front Med (Lausanne). 2020 Aug 26;7:462. doi: 10.3389/fmed.2020.00462. eCollection 2020. Front Med (Lausanne). 2020. PMID: 32984363 Free PMC article.
Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease.
Sánchez-Guijo F, Caballero-Velázquez T, López-Villar O, Redondo A, Parody R, Martínez C, Olavarría E, Andreu E, Prósper F, Díez-Campelo M, Regidor C, Villaron E, López-Corral L, Caballero D, Cañizo MC, Pérez-Simon JA. Sánchez-Guijo F, et al. Biol Blood Marrow Transplant. 2014 Oct;20(10):1580-5. doi: 10.1016/j.bbmt.2014.06.015. Epub 2014 Jun 19. Biol Blood Marrow Transplant. 2014. PMID: 24952358 Free article. Clinical Trial.
Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks.
Ocio EM, Maiso P, Chen X, Garayoa M, Alvarez-Fernández S, San-Segundo L, Vilanova D, López-Corral L, Montero JC, Hernández-Iglesias T, de Alava E, Galmarini C, Avilés P, Cuevas C, San-Miguel JF, Pandiella A. Ocio EM, et al. Blood. 2009 Apr 16;113(16):3781-91. doi: 10.1182/blood-2008-09-177774. Epub 2008 Nov 19. Blood. 2009. PMID: 19020308 Free article.
Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients.
Caballero-Velázquez T, López-Corral L, Encinas C, Castilla-Llorente C, Martino R, Rosiñol L, Sampol A, Caballero D, Serrano D, Heras I, San Miguel J, Pérez-Simón JA. Caballero-Velázquez T, et al. Br J Haematol. 2013 Aug;162(4):474-82. doi: 10.1111/bjh.12410. Epub 2013 Jun 15. Br J Haematol. 2013. PMID: 23772672 Free article. Clinical Trial.
Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients.
Paiva B, Gutiérrez NC, Chen X, Vídriales MB, Montalbán MÁ, Rosiñol L, Oriol A, Martínez-López J, Mateos MV, López-Corral L, Díaz-Rodríguez E, Pérez JJ, Fernández-Redondo E, de Arriba F, Palomera L, Bengoechea E, Terol MJ, de Paz R, Martin A, Hernández J, Orfao A, Lahuerta JJ, Bladé J, Pandiella A, Miguel JF; GEM (Grupo Español de Mieloma)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative. Paiva B, et al. Leukemia. 2012 Aug;26(8):1862-9. doi: 10.1038/leu.2012.42. Epub 2012 Feb 15. Leukemia. 2012. PMID: 22333880
122 results